Näytä suppeat kuvailutiedot

dc.contributor.authorElomaa, Hanna
dc.contributor.authorHärkönen, Jouni
dc.contributor.authorVäyrynen, Sara A.
dc.contributor.authorAhtiainen, Maarit
dc.contributor.authorOgino, Shuji
dc.contributor.authorNowak, Jonathan A.
dc.contributor.authorLau, Mai Chan
dc.contributor.authorHelminen, Olli
dc.contributor.authorWirta, Erkki-Ville
dc.contributor.authorSeppälä, Toni T.
dc.contributor.authorBöhm, Jan
dc.contributor.authorMecklin, Jukka-Pekka
dc.contributor.authorKuopio, Teijo
dc.contributor.authorVäyrynen, Juha P.
dc.date.accessioned2024-04-10T05:59:24Z
dc.date.available2024-04-10T05:59:24Z
dc.date.issued2024
dc.identifier.citationElomaa, H., Härkönen, J., Väyrynen, S. A., Ahtiainen, M., Ogino, S., Nowak, J. A., Lau, M. C., Helminen, O., Wirta, E.-V., Seppälä, T. T., Böhm, J., Mecklin, J.-P., Kuopio, T., & Väyrynen, J. P. (2024). Quantitative multiplexed analysis of indoleamine 2,3-dioxygenase (IDO) and arginase-1 (ARG1) expression and myeloid cell infiltration in colorectal cancer. <i>Modern Pathology</i>, <i>37</i>(4), Article 100450. <a href="https://doi.org/10.1016/j.modpat.2024.100450" target="_blank">https://doi.org/10.1016/j.modpat.2024.100450</a>
dc.identifier.otherCONVID_207188014
dc.identifier.urihttps://jyx.jyu.fi/handle/123456789/94237
dc.description.abstractIndoleamine 2,3-dioxygenase (IDO) and Arginase-1 (ARG1) are amino acid metabolizing enzymes frequently highly expressed in cancer. Their expression may deplete essential amino acids, lead to immunosuppression, and promote cancer growth. Still, their expression patterns, prognostic significance, and spatial localization in the colorectal cancer microenvironment are incompletely understood. Using a custom 10-plex immunohistochemistry assay and supervised machine learningbased digital image analysis, we characterized IDO and ARG1 expression in monocytic cells, granulocytes, mast cells, and tumor cells in 833 colorectal cancer patients. We evaluated the prognostic value and spatial arrangement of IDO and ARG1 expressing myeloid cells and tumor cells. IDO was mainly expressed by monocytic cells but also by some tumor cells, whereas ARG1 was predominantly expressed by granulocytes. Higher density of IDO+ monocytic cells was an independent prognostic factor for improved cancer-specific survival both in the tumor center (Ptrend=0.0002; HR for the highest ordinal category Q4 (vs Q1) 0.51, 95% CI 0.33–0.79) and the invasive margin (Ptrend=0.0015). Higher density of granulocytes was associated with prolonged cancer-specific survival in univariable models and higher FCGR3+ARG1+ neutrophil density in the tumor center also in multivariable analysis (Ptrend=0.0020). Granulocytes were, on average, located closer to tumor cells than monocytic cells. Furthermore, IDO+ monocytic cells and ARG1– granulocytes were closer than IDO– monocytic cells and ARG1+ granulocytes, respectively. The mRNA expression of the IDO1 gene was assessed in myeloid and tumor cells using publicly available single-cell RNA sequencing data for 62 colorectal cancers. IDO1 was mainly expressed in monocytes and dendritic cells, and high IDO1 activity in monocytes was associated with enriched immunostimulatory pathways. Our findings provided in-depth information about the infiltration patterns and prognostic value of cells expressing IDO and/or ARG1 in the colorectal cancer microenvironment highlighting the significance of host Journal Pre-proof immune response in tumor progression.en
dc.format.mimetypeapplication/pdf
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesModern Pathology
dc.rightsCC BY 4.0
dc.subject.otherbioimage analysis
dc.subject.othercolorectal carcinoma
dc.subject.othermultiplex immunohistochemistry
dc.subject.otherprognostic factors
dc.subject.otherspatial analysis
dc.subject.othertumor immunology
dc.titleQuantitative multiplexed analysis of indoleamine 2,3-dioxygenase (IDO) and arginase-1 (ARG1) expression and myeloid cell infiltration in colorectal cancer
dc.typearticle
dc.identifier.urnURN:NBN:fi:jyu-202404102803
dc.contributor.laitosLiikuntatieteellinen tiedekuntafi
dc.contributor.laitosBio- ja ympäristötieteiden laitosfi
dc.contributor.laitosMatemaattis-luonnontieteellinen tiedekuntafi
dc.contributor.laitosFaculty of Sport and Health Sciencesen
dc.contributor.laitosDepartment of Biological and Environmental Scienceen
dc.contributor.laitosFaculty of Mathematics and Scienceen
dc.type.urihttp://purl.org/eprint/type/JournalArticle
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.description.reviewstatuspeerReviewed
dc.relation.issn0893-3952
dc.relation.numberinseries4
dc.relation.volume37
dc.type.versionpublishedVersion
dc.rights.copyright© 2024 THE AUTHORS. Published by Elsevier Inc. on behalf of the United States & Canadian Academy of Pathology
dc.rights.accesslevelopenAccessfi
dc.subject.ysoimmunohistokemia
dc.subject.ysoimmunologia
dc.subject.ysosuolistosyövät
dc.subject.ysokarsinoomat
dc.subject.ysoennusteet
dc.format.contentfulltext
jyx.subject.urihttp://www.yso.fi/onto/yso/p26144
jyx.subject.urihttp://www.yso.fi/onto/yso/p18810
jyx.subject.urihttp://www.yso.fi/onto/yso/p25845
jyx.subject.urihttp://www.yso.fi/onto/yso/p28373
jyx.subject.urihttp://www.yso.fi/onto/yso/p3297
dc.rights.urlhttps://creativecommons.org/licenses/by/4.0/
dc.relation.doi10.1016/j.modpat.2024.100450
jyx.fundinginformationThis study was funded by Cancer Foundation Finland (59-5619 to JPV and to HE), Emil Aaltonen Foundation (220022K to HE), Orion Research Foundation sr (to HE), Päivikki and Sakari Sohlberg Foundation (to HE), Sigrid Jusélius Foundation (230229 to JPV), and the State Research Funding (to JPV and to HE). T.T.S. was supported by research grants from Jane and Aatos Erkko Foundation, Sigrid Jusélius Foundation, Finnish Medical Foundation, Emil Aaltonen Foundation, Cancer Foundation Finland, Relander Foundation, and the State Research Funding.
dc.type.okmA1


Aineistoon kuuluvat tiedostot

Thumbnail

Aineisto kuuluu seuraaviin kokoelmiin

Näytä suppeat kuvailutiedot

CC BY 4.0
Ellei muuten mainita, aineiston lisenssi on CC BY 4.0